With a strong and profitable base, Microbix' greatest opportunities to grow the Company and increase shareholder value are found in its pipeline programs with three near-term opportunities each of which could generate annual revenues of $50M to $100M.
- VIRUSMAX(TM), a proprietary influenza vaccine production enhancement technology. - KINLYTIC(TM) (urokinase), a thrombolytic agent indicated for the treatment of acute massive pulmonary embolism. - SST(TM), (Semen Sexing Technology), a technology that will allow livestock producers to pre-select the sex of offspring before conception.
Pandemic and Seasonal Influenza Manufacturing: VIRUSMAX
Earlier this week, Microbix announced it signed a joint venture agreement with the Hunan Biopharmaceutical Co. Ltd. (a Hunan Province state-owned enterprise) for initial financing to construct Asia's largest influenza vaccine production facility and the third largest vaccine plant in the world.
The facility, for which construction will begin in early 2010 and be fully operational by 2013, will be designed around Microbix VIRUSMAX(TM) vaccine technology. More than five years in development at Microbix, VIRUSMAX is designed to increase influenza vaccine yields and has demonstrated an average yield increase of two-fold over current production methods.
The agreement forms an equal partnership joint venture to build and operate a state-of-the-art influenza vaccine facility, located in Changsha National Biomedical Park near Changsha City, the capital of Hunan Province, which will have the capacity to produce
|SOURCE Microbix Biosystems Inc.|
Copyright©2009 PR Newswire.
All rights reserved